1
|
Sebesta I, Stiburkova B, Krijt J. Hereditary xanthinuria is not so rare disorder of purine metabolism. Nucleosides Nucleotides Nucleic Acids 2018; 37:324-328. [PMID: 29723117 DOI: 10.1080/15257770.2018.1460478] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Hereditary xanthinuria (type I) is caused by an inherited deficiency of the xanthine oxidorectase (XDH/XO), and is characterized by very low concentration of uric acid in blood and urine and high concentration of urinary xanthine, leading to urolithiasis. Type II results from a combined deficiency of XDH/XO and aldehyde oxidase. Patients present with hematuria, renal colic, urolithiasis or even acute renal failure. Clinical symptoms are the same for both types. In a third type, clinically distinct, sulfite oxidase activity is missing as well as XDH/XO and aldehyde oxidase. The prevalence is not known, but about 150 cases have been described so far. Hypouricemia is sometimes overlooked, that´s why we have set up the diagnostic flowchart. This consists of a) evaluation of uric acid concentrations in serum and urine with exclusion of primary renal hypouricemia, b) estimation of urinary xanthine, c) allopurinol loading test, which enables to distinguish type I and II; and finally assay of xanthine oxidoreductase activity in plasma with molecular genetic analysis. Following this diagnostic procedure we were able to find first patients with hereditary xanthinuria in our Czech population. We have detected nine cases, which is one of the largest group worldwide. Four patients were asymptomatic. All had profound hypouricemia, which was the first sign and led to referral to our department. Urinary concentrations of xanthine were in the range of 170-598 mmol/mol creatinine (normal < 30 mmol/mol creatinine). Hereditary xanthinuria is still unrecognized disorder and subjects with unexplained hypouricemia need detailed purine metabolic investigation.
Collapse
Affiliation(s)
- I Sebesta
- a Institute of Inherited Metabolic Disorders, First Faculty of Medicine , Charles University , Prague , Czech Republic.,b Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine , Charles University , Prague , Czech Republic
| | - B Stiburkova
- a Institute of Inherited Metabolic Disorders, First Faculty of Medicine , Charles University , Prague , Czech Republic.,c Institute of Rheumatology, First Faculty of Medicine , Charles University , Prague , Czech Republic
| | - J Krijt
- a Institute of Inherited Metabolic Disorders, First Faculty of Medicine , Charles University , Prague , Czech Republic
| |
Collapse
|
2
|
Inazu T, Kawahara T, Endou H, Anzai N, Sebesta I, Stiburkova B, Ichida K, Hosoyamada M, Testa A, Testa A, Leonardis D, Catalano F, Pisano A, Mafrica A, Spoto B, Sanguedolce MC, Parlongo RM, Tripepi G, Postorino M, Enia G, Zoccali C, Mallamaci F, Working Group* M, Luque de Pablos A, Garcia-Nieto V, Lopez-Menchero JC, Ramos-Trujillo E, Gonzalez-Acosta H, Claverie-Martin F, Arsali M, Demosthenous P, Papazachariou L, Athanasiou Y, Voskarides K, Deltas C, Pierides A, Lee S, Jeong KH, Ihm C, Lee TW, Lee SH, Moon JY, Wi JG, Lee HJ, Kim EY, Rogacev K, Friedrich A, Hummel B, Berg J, Zawada A, Fliser D, Geisel J, Heine GH, Brabcova I, Brabcova I, Dusilova-Sulkova S, Dusilova-Sulkova S, Krejcik Z, Stranecky V, Lipar K, Marada T, Stepankova J, Viklicky O, Buraczynska M, Zukowski P, Zaluska W, Kuczmaszewska A, Ksiazek A, Gaggl M, Weidner S, Hofer M, Kleinert J, Fauler G, Wallner M, Kotanko P, Sunder-Plassmann G, Paschke E, Heguilen R, Heguilen R, Albarracin L, Politei J, Liste AA, Bernasconi A, Kusano E, Russo R, Pisani A, Messalli G, Imbriaco M, Prikhodina L, Ryzhkova O, Polyakov V, Lipkowska K, Ostalska-Nowicka D, Smiech M, Jaroniec M, Zaorska K, Szaflarski W, Nowicki M, Zachwieja J, Spoto B, Spoto B, Testa A, Sanguedolce MC, D'arrigo G, Parlongo RM, Pisano A, Tripepi G, Zoccali C, Mallamaci F, Moskowitz J, Piret S, Tashman A, Velez E, Lhotta K, Thakker R, Kotanko P, Cox J, Kingswood J, Mbundi J, Attard G, Patel U, Saggar A, Elmslie F, Doyle T, Jansen A, Jozwiak S, Belousova E, Frost M, Kuperman R, Bebin M, Korf B, Flamini R, Kohrman M, Sparagana S, Wu J, Ford J, Shah G, Franz D, Zonnenberg B, Cheung W, Urva S, Wang J, Frost M, Kingswood C, Budde K, Kofman T, Narjoz C, Raimbourg Q, Roland M, Loriot MA, Karras A, Hill GS, Jacquot C, Nochy D, Thervet E, Jagodzinski P, Mostowska M, Oko A, Nicolaou N, Kevelam S, Lilien M, Oosterveld M, Goldschmeding R, Van Eerde A, Pfundt R, Sonnenberg A, Ter Hal P, Knoers N, Renkema K, Storm T, Nielsen R, Christensen E, Frykholm C, Tranebjaerg L, Birn H, Verroust P, Neveus T, Sundelin B, Hertz JM, Holmstrom G, Ericson K, Fabris A, Cremasco D, Zambon A, Muraro E, Alessi M, D'angelo A, Anglani F, Del Prete D, Alkmim Teixeira A, Quinto BM, Jose Rodrigues C, Beltrame Ribeiro A, Batista M, Kerti A, Kerti A, Csohany R, Szabo A, Arkossy O, Sallai P, Moriniere V, Vega-Warner V, Lakatos O, Szabo T, Reusz G, Tory K, Addis M, Anglani F, Tosetto E, Meloni C, Ceol M, Cristofaro R, Melis MA, Vercelloni P, D'angelo A, Marra G, Kaniuka S, Nagel M, Wolyniec W, Obolonczyk L, Swiatkowska-Stodulska R, Sworczak K, Rutkowski B, Chen C, Jiang L, Chen L, Fang L, Mozes M. M, Boosi M, Rosivall L, Kokeny G, Diana R, Gross O, Johanna T, Rainer G, Ayse C, Henrik H, Gerhard-Anton M, Nabil M, Intissar E, Belge H, Belge H, Bloch J, Dahan K, Pirson Y, Vanhille P, Demoulin N. Genetic diseases. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Stiburkova B, Sebesta I, Ichida K, Hosoyamada M. Analysis of patients with renal hypouricemia in Czech population. N Biotechnol 2010. [DOI: 10.1016/j.nbt.2010.01.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
4
|
Sebesta I, Stiburková B, Dvorakova L, Hrebicek M, Minks J, Stolnaja L, Vernerova Z, Rychlik I. Unusual presentation of Kelley-Seegmiller syndrome. Nucleosides Nucleotides Nucleic Acids 2008; 27:648-55. [PMID: 18600521 DOI: 10.1080/15257770802143863] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Female carriers of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency have somatic cell mosaicism of HPRT activity and are healthy. We report a 50-year-old woman without gout or nephrolithiasis. She was never on allopurinol. Normal serum uric acid concentrations, increased plasma hypoxanthine, and xanthine were found. HPRT activity in erythrocytes was surprisingly low: at 8.6 nmol h(-1) mg (-1) haemoglobin. Mutation analysis revealed a heterozygous HPRT gene mutation, c.215A > G (p.Tyr72Cys). Assessment of X-inactivation ratio has shown that > 75% of the active X-chromosome bears the mutant allele and could explain these unusual, previously undescribed findings.
Collapse
Affiliation(s)
- I Sebesta
- Institute of Inherited Metabolic Disorders, Charles University, Prague, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Vernerová Z, Rychlík I, Brunerová L, Dvoráková L, Pavelková A, Sebesta I. An unusual cause of renal amyloidosis secondary to gout: the first description of familial occurrence. Nucleosides Nucleotides Nucleic Acids 2007; 25:1305-8. [PMID: 17065112 DOI: 10.1080/15257770600893941] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND AA amyloidosis caused by the chronic inflammation accompanying gouty arthritis is extremely rare and familial occurrence has not been described so far. CASE REPORT We present the case of two brothers (47 and 44 years old) with 7- and 10-year history of hyperuricaemia and chronic tophaceous gout with polyarticular involvement. The enzymatic assay performed in their erythrocytes proved the partial hypoxanthine-guanine phosphoribosyl transferase deficiency (Kelley-Seegmiller syndrome), the genetic defect of purine metabolism. Later on they developed proteinuria and chronic renal insufficiency /CRI/. Renal biopsy disclosed the combination of AA amyloidosis and gouty nephropathy in both the cases. Despite the standard treatment the older brother progressed to chronic renal failure. On the contrary, the younger one being longterm treated with oral colchicin have stabilized CRI. CONCLUSIONS Only several cases of AA renal amyloidosis until recently, secondary to gout have been reported. Our case represents the first report of familial occurrence of this extremely rare disease.
Collapse
Affiliation(s)
- Z Vernerová
- Department of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Excretion fraction of uric acid (EFUA), is one of the most important hallmarks for diagnosis of familial juvenile hyperuricemic nephropathy (FJHN) and hereditary renal hypouricemia. EFUA was measured in 20 patients with FJHN. However, low excretion fraction (<6%) was found also in healthy FJHN family members and healthy controls (ref. ranges EFUA: men 6-12%, women 6-20%). Similar finding of low EFUA was reported recently. Distribution of EFUA was further studied in 2,416 healthy controls, which were selected from 6,000 samples and divided according to age. In conclusion, finding of low EFUA in family members is a risk factor for renal damage and indication for purine metabolic investigations with subsequent molecular biology analysis. As EFUA could be found also in healthy controls--it should be interpreted with care and other features of FJHN (such as hyperuricemia, progressive renal disease in family) should be taken to account.
Collapse
Affiliation(s)
- B Stibůrková
- Institute of Inherited Metabolic Disorders, Charles University 1st School of Medicine, Prague, Czech Republic
| | | | | | | |
Collapse
|
7
|
Abstract
Purines and pyrimidines form the backbone of DNA and RNA. Hence, modification of purine and pyrimidine metabolism can have serious effects on normal functioning of a subject. These aspects formed the main topics for an International and a European Series of meetings, dedicated to the metabolism in man. In order to streamline the organization of these meetings the European Society was transformed to an International society: the Purine and Pyrimidine Society (www.ppsociety.org). This special issue of Nucleosides, Nucleotides, and, Nucleic, Acids highlights the last European meeting in Prague, focusing on inborn errors, cardiac diseases, inflammatory diseases, rheumatology, haematology, cancer, virology, genetic polymorphism, specific methodology, and, of course, metabolism. The meeting in Chicago in 2007 will be the first meeting of the Purine and Pyrimidine Society.
Collapse
Affiliation(s)
- G J Peters
- Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
| | | | | |
Collapse
|
8
|
Stibůrková B, Sebesta I, Kmoch S. [Diagnostic aspects of familial juvenile hyperuriceamic nephropathy]. Cas Lek Cesk 2005; 144:466-71. [PMID: 16161539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
UNLABELLED BACKGROUND; Familial juvenile hyperuricemic nephropathy (FJHN) is a genetic disorder with the autosomal dominant mode of hereditability; characterized with hyperuricemia, gout and progressive renal disease. Characterization of the disease together with clinical and biochemical findings in patients of Czech population is described. METHODS AND RESULTS The bloodlines of three Czech families with FJHN were set up on the basis of their family history. The specimens of blood and urine were taken from 57 family members for biochemical investigations and isolations of genomic DNA. Blood and urinary concentrations of the uric acid and creatinine together with values of excretion fraction of uric acid and Kaufman's index were determined. Based on these results diagnosis of FJHN was established or confirmed in 19 patients. One additional patient was diagnosed on the results of linkage analysis. CONCLUSIONS FJHN is a disorder sharing non-specific clinical and biochemical signs with the group of familial renal disorders. The effective diagnosis is difficult due to the heterogeneity of the disorder and limited availability of molecular genetic analysis. Detailed purine metabolic investigation together with precise family history is thus necessary and very important in family members with hyperuricemia and/or gout (particularly in childhood or young women) as well as in patients with familial renal disease.
Collapse
Affiliation(s)
- B Stibůrková
- Ustav dĕdicných metabolických poruch 1. LF UK, Praha.
| | | | | |
Collapse
|
9
|
Kmoch S, Hartmannová H, Stibůrková B, Krijt J, Zikánová M, Sebesta I. Human adenylosuccinate lyase (ADSL), cloning and characterization of full-length cDNA and its isoform, gene structure and molecular basis for ADSL deficiency in six patients. Hum Mol Genet 2000; 9:1501-13. [PMID: 10888601 DOI: 10.1093/hmg/9.10.1501] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Adenylosuccinate lyase (ADSL) is a bifunctional enzyme acting in de novo purine synthesis and purine nucleotide recycling. ADSL deficiency is a selectively neuronopathic disorder with psychomotor retardation and epilepsy as leading traits. Both dephosphorylated enzyme substrates, succinylaminoimidazole-carboxamide riboside (SAICAr) and succinyladenosine (S-Ado), accumulate in the cerebrospinal fluid (CSF) of affected individuals with S-Ado/SAICAr concentration ratios proportional to the phenotype severity. We studied the disorder at various levels in a group of six patients with ADSL deficiency. We identified the complete ADSL cDNA and its alternatively spliced isoform resulting from exon 12 skipping. Both mRNA isoforms were expressed in all the tissues studied with the non-spliced form 10-fold more abundant. Both cDNAs were expressed in Escherichia coli and functionally characterized at the protein level. The results showed only the unspliced ADSL to be active. The gene consists of 13 exons spanning 23 kb. The promotor region shows typical features of the housekeeping gene. Eight mutations were identified in a group of six patients. The expression studies of the mutant proteins carried out in an attempt to study genotype-phenotype correlation showed that the level of residual enzyme activity correlates with the severity of the clinical phenotype. All the mutant enzymes studied in vitro displayed a proportional decrease in activity against both of their substrates. However, this was not concordant with strikingly different concentration ratios in the CSF of individual patients. This suggests either different in vivo enzyme activities against each of the substrates and/or their different turnover across the CSF-blood barrier, which may be decisive in determining disease severity.
Collapse
Affiliation(s)
- S Kmoch
- Institute for Inherited Metabolic Disorders, Department of Clinical Biochemistry, Charles University 1st School of Medicine and General Faculty Hospital, Prague, Czech Republic.
| | | | | | | | | | | |
Collapse
|
10
|
Stibůrková B, Majewski J, Sebesta I, Zhang W, Ott J, Kmoch S. Familial juvenile hyperuricemic nephropathy: localization of the gene on chromosome 16p11.2-and evidence for genetic heterogeneity. Am J Hum Genet 2000; 66:1989-94. [PMID: 10780922 PMCID: PMC1378048 DOI: 10.1086/302936] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2000] [Accepted: 04/10/2000] [Indexed: 11/03/2022] Open
Abstract
Familial juvenile hyperuricemic nephropathy (FJHN), is an autosomal dominant renal disease characterized by juvenile onset of hyperuricemia, gouty arthritis, and progressive renal failure at an early age. Using a genomewide linkage analysis in three Czech affected families, we have identified, on chromosome 16p11.2, a locus for FJHN and have found evidence for genetic heterogeneity and reduced penetrance of the disease. The maximum two-point LOD score calculated with allowance for heterogeneity (HLOD) was 4.70, obtained at recombination fraction 0, with marker D16S3036; multipoint linkage analysis yielded a maximum HLOD score of 4.76 at the same location. Haplotype analysis defined a 10-cM candidate region between flanking markers D16S501 and D16S3113, exhibiting crossover events with the disease locus. The candidate interval contains several genes expressed in the kidney, two of which-uromodulin and NADP-regulated thyroid-hormone-binding protein-represent promising candidates for further analysis.
Collapse
Affiliation(s)
- B Stibůrková
- Institute for Inherited Metabolic Disorders, 128 00 Prague 2, Czech Republic
| | | | | | | | | | | |
Collapse
|
11
|
Wang L, Ou X, Sebesta I, Vondrak K, Krijt J, Elleder M, Poupetova H, Ledvinova J, Zeman J, Simmonds HA, Tischfield JA, Sahota A. Combined adenine phosphoribosyltransferase and N-acetylgalactosamine-6-sulfate sulfatase deficiency. Mol Genet Metab 1999; 68:78-85. [PMID: 10479485 DOI: 10.1006/mgme.1999.2893] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We describe a Czech patient with combined adenine phosphoribosyltransferase (APRT) deficiency (2,8-dihydroxyadenine urolithiasis) and N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency (mucopolysaccharidosis Type IVA, Morquio disease A). Adenine and its extremely insoluble derivative, 2,8-dihydroxyadenine, were identified in the urine, and APRT deficiency was confirmed in erythrocytes. There was excessive excretion of keratan sulfate in the urine, and GALNS deficiency was confirmed in leukocytes. GALNS and APRT are both located on chromosome 16q24.3, suggesting that the patient had a deletion involving both genes. PCR amplification of genomic DNA indicated that a novel junction was created by the fusion of sequences distal to GALNS exon 2 and proximal to APRT exon 3, and that the size of the deleted region was approximately 100 kb. The deletion breakpoints were localized within GALNS intron 2 and APRT intron 2. Several other genes, including the alpha subunit of cytochrome B (CYBA), which is deleted or mutated in the autosomal form of chronic granulomatous disease, are located in the 16q24.3 region, but PCR amplification showed that this gene was present in the proband. A patient with hemizygosity for GALNS deficiency and APRT deficiency has been reported from Japan recently. These findings indicate that: (i) APRT is located telomeric to GALNS; (ii) GALNS and APRT are transcribed in the same orientation (centromeric to telomeric); and (iii) combined APRT/GALNS deficiency may be more common than hitherto realized.
Collapse
Affiliation(s)
- L Wang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Krijt J, Kmoch S, Hartmannová H, Havlícek V, Sebesta I. Identification and determination of succinyladenosine in human cerebrospinal fluid. J Chromatogr B Biomed Sci Appl 1999; 726:53-8. [PMID: 10348170 DOI: 10.1016/s0378-4347(99)00024-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Succinyladenosine (S-Ado) is a biochemical marker of adenylosuccinase deficiency--the genetic defect of purine de novo synthesis. S-Ado has been previously reported as normally undetectable in cerebrospinal fluid (CSF) of children not suffering from this defect. In present study, we employed solid-phase extraction and thin-layer chromatography for isolation of a compound with spectral and chromatographic characteristics identical to S-Ado from human CSF. The high-performance liquid chromatography-negative-ion electrospray ionization mass spectrometry analysis confirmed that the isolated compound is S-Ado. We established the reference values of S-Ado in CSF of children (1.1+/-0.4 micromol/l; mean +/- S.D; n = 26) by means of reversed-phase HPLC method on a C18 column with UV detection.
Collapse
Affiliation(s)
- J Krijt
- Institute for Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | | | | | | |
Collapse
|
13
|
Affiliation(s)
- I Sebesta
- Department of Clinical Biochemistry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | | | | | | | | | | |
Collapse
|
14
|
Pavelka K, Sebesta I, Blovská J, Malý J, Chadimová M. [Familial juvenile gouty nephropathy]. Cas Lek Cesk 1996; 135:668-71. [PMID: 8998814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The authors present the description of a family comprising father (his mother had died middle-aged from renal failure) and his two children aged 15 and 17 years who developed is young age (already in the second decade) gouty arthritis and primary interstitial nephritis. Based on the laboratory finding of hyperuricaemia with disproportionately low urate excretion and excretion of excessive uric acid formation, an enzyme defect and other renal disease the authors diagnosed familial gouty juvenile nephropathy. This diagnosis was confirmed also by histological examination of renal biopsy in the youngest member of the family. It is a disease which belongs into the group of hereditary types of nephritis. In the literature worldwide some nine families were described, in the Czech Republic it is the first description of this condition.
Collapse
Affiliation(s)
- K Pavelka
- Centrum dĕdicných metabolických poruch, Praha
| | | | | | | | | |
Collapse
|
15
|
Giacomello A, Peters GJ, Eriksson S, Abreu R, Kristensen T, Munch-Petersen B, Vincenzetti S, Cambi A, Neuhard J, Garattini E, Vita A, Oka J, Matsumoto A, Hosokawa Y, Inoue S, Allegrini S, Johnson RB, Fiol CJ, Eriksson S, Fabianowska-Majewska K, Wasiak T, Duley J, Simmonds A, Bretner M, Felczak K, Poznański J, Dzik JM, Golos B, Jarmuła A, Rode W, Kulikowski T, Codacci-Pisanelli G, Pinedo HM, Noordhuis P, Groeningen CJ, Wilt CL, Franchi F, Hatse S, Balzarini J, Clercq E, Marinello E, Rosi F, Dispensa E, Mangiavacchi P, Riario-Sforza G, Agostinho AB, Smolenski RT, Müller MM, Roch-Ramel F, Guisan B, Diezi J, Tavenier M, Skladanowski AC, Abreu RA, Jong JW, Åmellem Ø, Löffler M, Pettersen EO, Boulieu R, Lenoir A, Bertocchi M, Mornex JF, Makarewicz W, Spychala J, Mitchell BS, Barankiewcz J, Góra-Tybor J, Robak T, Spasokukotskaja T, Sasvári-Székely M, Piróth Z, Kazimierczuk Z, Staub M, Keuzenkamp-Jansen CW, Abreu RA, Bökkerink JPM, Trijbels JMF, Eriksson S, Warzocha K, Krykowski E, Góra-Tybor J, Fronczak A, Robak T, Minelli A, Moroni M, Monacelli N, Mezzasoma I, Amici A, Emanuelli M, Raffaelli N, Ruggieri S, Magni G, Carta MC, Mattana A, Poddie F, Sgarrella F, Tozzi MG, Veerman G, Ruiz van Haperen VWT, Moorsel CJA, Pesi R, Baiocchi C, Camici M, Ipata PL, Kozłowska M, Świerczyński J, Smoleński RT, Jastorff B, Messina E, Savini F, Procopio A, Giacomello A, Wielgus-Kutrowska B, Kulikowska E, Wierzchowski J, Bzowska A, Shugar D, Fairbanks LD, Ruckemann K, Simmonds HA, Kaletha K, Szymańska G, Thebault M, Raffin JP, Gal Y, Griesmacher A, Abreu RA, Zych M, Ruckemann K, Jagodzinski P, Kochan Z, Stolk J, Boerbooms A, Abreu R, Koning D, Putte L, Fiorini M, Bazzichi L, Bertolini G, Martini C, Ciompi ML, Lucacchini A, Pizzichini M, Terzuoli L, Arezzini L, Fe L, Pagani R, Miscetti P, Allegrucci C, Sebesta I, Duley JA, Simmonds HA, Gross M, Salerno C, Stone TW, Berghe G, Valik D, Jones JD, Guerranti R, Fè L, Sforza GR, Knecht W, Grein K, Lodi R, Iotti S, Barbiroli B, Bonin B, Chantin C, Bory C, Micheli V, Jacomelli G, Morozzi G, Fioravanti A, Marcolongo R, Pompucci G, Peters GJ, Noordhuis P, Komissarov A, Holwerda U, Kok RM, Laar JAM, Wilt CL, Groeningen CJ, Pinedo HM, Perrett D, Jacobsson B, Sisto A, Iezzi A, Carlo M, Pizzigallo E, Akhondzadeh S, MacGregor DG, Ogilvy HV, Zoref-Shani E, Brosh S, Sidi Y, Bromberg Y, Sperling O, Gennip AH, Abeling NGGM, Stroomer AEM, Lenthe H, Bakker HD, Kuilenburg ABP, Connolly GP, Abbott NJ, Lilling G, Gozes I, Vreken P, Meinsma R, Ahreu RA, Diasio RB, Albin N, Johnson MR, Shahinian H, Wang K, Gathof BS, Rocchigiani M, Puig JG, Mateos F, Sestini S, Krijt J, Shin Y, Gresser U, Costa A, Maximova N, Andolina M, Paci M, Carrozzi M, Osbich A, Durighello M, Cavalli F, Geatti O, Zammarchi E, Morgan G, Webster ADB, Slavin S, Naparstek E, Nagler A, Acker M, Cividalli G, Kapellushnik Y, Varadi G, Ben-Yoseph R, Or R, Parfenov VV, Ignatenko MA, Amchenkova AM, Narovlyansky AN, Spoto G, Mastropasqua L, Gizzi F, Arduini A, Gallo P, Ciancaglini M, Gallenga PE, Šebesta I, Zeman J, Crifò C, Vito M, Lomonte A, Gerber G, Carlucci F, Tabucchi A, Vannoni P, Pietro MC, Vincent MF, Bontemps F, Boer P, Rötzer E, Ehrmann D, Empl W, Bride MBM, Ogg CS, Cameron JS, Moro F, Rigden S, Rees L, Hoff WV, Raman V, Palmieri P, Mastropierro G, Albertazzi A, Rucci C, Darlington LG, Cotton SR, Gorter JJ, Lawrence ES, Petrie A, Sarsam RP, Semple MJ, Warburton EA, Quaratino CP, Talone L, Sciascio N, Hrebíček MH, Poupětová H, Ledvinová J, Elleder M, Vondrák K, Rees PC, Wonke B, Thein SL, Clegg JB, Marlewski M, Pennelli A, Marzio M, Angelini G, Sabatino G, Koning P, Kerstens P, Graaf R, Hayek G, Cardona F. Preface. Pharm World Sci 1995; 17:K4-K4. [DOI: 10.1007/bf01875184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/15/2023]
|
16
|
Affiliation(s)
- J Krijt
- Centre for Metabolic Disorders, Charles University, Prague
| | | | | | | | | |
Collapse
|
17
|
Affiliation(s)
- I Sebesta
- Department of Clinical Biochemistry, Charles University, Prague, Czech Republic
| | | | | | | | | | | |
Collapse
|
18
|
Sebesta I, Fairbanks LD, Davies PM, Simmonds HA, Leonard JV. The allopurinol loading test for identification of carriers for ornithine carbamoyl transferase deficiency: studies in a healthy control population and females at risk. Clin Chim Acta 1994; 224:45-54. [PMID: 8174277 DOI: 10.1016/0009-8981(94)90119-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The increase in orotidine excretion following a 300 mg allopurinol dose has been used for carrier detection in ornithine carbamoyl transferase (OCT) deficiency. This test was evaluated, using three collection periods, in 23 healthy women, 4 obligate heterozygotes and 32 other women at risk of being carriers of OCT deficiency. Four methods for the analysis of orotidine and orotic acid were compared. Using the most reproducible method, the excretion of orotic acid in controls was found to be consistently higher than that of orotidine in all three periods. The distribution of both orotic acid and orotidine excretion of controls was skewed so that standard deviations (S.D.) were calculated after logarithmic transformation. All four obligate heterozygotes showed orotic acid and orotidine excretion in excess of 3 S.D. above the control mean and a further 7 women had one or more excretion values in excess of 3 S.D., while 16 gave a value of less than 2 S.D. for both metabolites. We conclude that the predictive value of the test is good, that both orotic acid and orotidine should be measured to reduce the risk of misclassification and that values greater than 2 S.D. for both in one or more periods should be used as the cut-off point to identify carriers.
Collapse
Affiliation(s)
- I Sebesta
- Purine Research Laboratory, Guy's Hospital, London Bridge, UK
| | | | | | | | | |
Collapse
|
19
|
Affiliation(s)
- I Sebesta
- Department of Clinical Biochemistry, 1st Medical Faculty, Charles University, Prague, Czech Republic
| | | | | | | |
Collapse
|
20
|
Affiliation(s)
- I Sebesta
- Department of Clinical Biochemistry, 1st Medical Faculty, Charles University, Prague, Czechoslovakia
| | | | | | | |
Collapse
|